NCAM1 and neuroblastoma: At relapse, bone marrow DTCs reached 1.59%, but tumor cells were negative for GD2 and the fraction of CD56-expressing cells was lower, while all tumor cells carried the neuroblastoma-typical MYCN oncogene amplification (Fig. 3B & E).